المؤلفون: Harnden AC, Davis OA, Box GM, Hayes A, Johnson LD, Henley AT, de Haven Brandon AK, Valenti M, Cheung KJ, Brennan A, Huckvale R, Pierrat OA, Talbot R, Bright MD, Akpinar HA, Miller DSJ, Tarantino D, Gowan S, de Klerk S, McAndrew PC, Le Bihan YV, Meniconi M, Burke R, Kirkin V, van Montfort RLM, Raynaud FI, Rossanese OW, Bellenie BR, Hoelder S

المصدر: Journal of medicinal chemistry [J Med Chem] 2023 Apr 27; Vol. 66 (8), pp. 5892-5906. Date of Electronic Publication: 2023 Apr 07.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse*/pathology , Quinolones*, Animals ; Humans ; Mice ; Cell Line, Tumor ; Disease Models, Animal ; Proto-Oncogene Proteins c-bcl-6/chemistry ; Transcription Factors

المؤلفون: Huckvale R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Harnden AC; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Cheung KJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Pierrat OA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Talbot R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Box GM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Henley AT; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., de Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Hallsworth AE; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Bright MD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Akpinar HA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Miller DSJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Tarantino D; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Gowan S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Hayes A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Gunnell EA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K., Brennan A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Davis OA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Johnson LD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., de Klerk S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., McAndrew C; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K., Meniconi M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Burke R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Kirkin V; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Rossanese OW; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Bellenie BR; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.

المصدر: Journal of medicinal chemistry [J Med Chem] 2022 Jun 23; Vol. 65 (12), pp. 8191-8207. Date of Electronic Publication: 2022 Jun 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Carcinogenesis* , Gene Expression Regulation, Neoplastic*, Animals ; Humans ; Mice ; Proto-Oncogene Proteins c-bcl-6/metabolism

المؤلفون: Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Mak GWY; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Gurden MD; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Xavier CPR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., O'Fee L; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Schmitt J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., vanMontfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

المصدر: British journal of cancer [Br J Cancer] 2017 Apr 25; Vol. 116 (9), pp. 1166-1176. Date of Electronic Publication: 2017 Mar 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Proteins/*genetics , Heterocyclic Compounds, 4 or More Rings/*administration & dosage , M Phase Cell Cycle Checkpoints/*drug effects , Neoplasms/*drug therapy , Protein Kinase Inhibitors/*administration & dosage , Protein Serine-Threonine Kinases/*genetics , Protein-Tyrosine Kinases/*genetics, Animals ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Line, Tumor ; HCT116 Cells ; Humans ; Mice ; Neoplasms/genetics ; Neoplasms/pathology ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Xenograft Model Antitumor Assays

المؤلفون: Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM; Sareum Ltd. , Cambridge CB22 3FX, U.K., Lamers MB; Sareum Ltd. , Cambridge CB22 3FX, U.K., Reader JC; Sareum Ltd. , Cambridge CB22 3FX, U.K., Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I

المصدر: Journal of medicinal chemistry [J Med Chem] 2016 Jun 09; Vol. 59 (11), pp. 5221-37. Date of Electronic Publication: 2016 May 23.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: 4-Aminopyridine/*analogs & derivatives , Checkpoint Kinase 1/*antagonists & inhibitors , Protein Kinase Inhibitors/*pharmacology , Pyrazines/*pharmacology, 4-Aminopyridine/chemical synthesis ; 4-Aminopyridine/chemistry ; 4-Aminopyridine/pharmacology ; Checkpoint Kinase 1/metabolism ; Dose-Response Relationship, Drug ; Humans ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrazines/chemical synthesis ; Pyrazines/chemistry ; Structure-Activity Relationship

المؤلفون: Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eve PD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Henley AT; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Boxall KJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Tall M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Swales K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Matthews TP; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., McHardy T; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Lainchbury M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Osborne J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hunter JE; Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle Upon Tyne, UK., Perkins ND; Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle Upon Tyne, UK., Aherne GW; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Reader JC; Sareum Ltd, Cambridge, UK., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Collins I; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Garrett MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; School of Biosciences, University of Kent, Canterbury, Kent, UK.

المصدر: Oncotarget [Oncotarget] 2016 Jan 19; Vol. 7 (3), pp. 2329-42.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

مواضيع طبية MeSH: Xenograft Model Antitumor Assays*, 4-Aminopyridine/*analogs & derivatives , Carcinoma, Non-Small-Cell Lung/*drug therapy , Checkpoint Kinase 1/*drug effects , Lung Neoplasms/*drug therapy , Lymphoma, B-Cell/*drug therapy , Proto-Oncogene Proteins c-myc/*genetics , Proto-Oncogene Proteins p21(ras)/*genetics , Pyrazines/*pharmacology, 4-Aminopyridine/pharmacokinetics ; 4-Aminopyridine/pharmacology ; Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; CDC2 Protein Kinase ; Camptothecin/analogs & derivatives ; Camptothecin/pharmacology ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Checkpoint Kinase 1/metabolism ; Checkpoint Kinase 2/antagonists & inhibitors ; Cyclin-Dependent Kinases/antagonists & inhibitors ; DNA Damage/drug effects ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Drug Synergism ; HT29 Cells ; Humans ; Irinotecan ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mice, Transgenic ; Pyrazines/pharmacokinetics ; Gemcitabine

المؤلفون: Lainchbury M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG U. K., Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Garrett MD, Collins I

المصدر: Journal of medicinal chemistry [J Med Chem] 2012 Nov 26; Vol. 55 (22), pp. 10229-40. Date of Electronic Publication: 2012 Oct 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacology , Antineoplastic Agents/*pharmacology , Colonic Neoplasms/*drug therapy , Neuroblastoma/*drug therapy , Protein Kinase Inhibitors/*pharmacology , Protein Kinases/*chemistry , Pyrimidines/*pharmacology, Administration, Oral ; Aminopyridines/chemical synthesis ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemical synthesis ; Checkpoint Kinase 1 ; Child ; Colonic Neoplasms/enzymology ; DNA Damage/drug effects ; Drug Design ; Humans ; Mice ; Mice, Nude ; Mice, Transgenic ; N-Myc Proto-Oncogene Protein ; Neuroblastoma/enzymology ; Nuclear Proteins/genetics ; Oncogene Proteins/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinases/metabolism ; Pyrimidines/chemical synthesis ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays

المؤلفون: Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom. Mike.Walton@icr.ac.uk, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2012 Oct 15; Vol. 18 (20), pp. 5650-61. Date of Electronic Publication: 2012 Aug 28.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms, Experimental*/drug therapy , Neoplasms, Experimental*/metabolism , Neuroblastoma*/drug therapy , Neuroblastoma*/metabolism , Protein Kinases*/genetics , Protein Kinases*/metabolism, Aminopyridines/*administration & dosage , Pyrimidines/*administration & dosage, Administration, Oral ; Animals ; Antineoplastic Agents/administration & dosage ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Cycle Checkpoints/drug effects ; Checkpoint Kinase 1 ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Mice ; Mice, Transgenic ; Protein Kinase Inhibitors/administration & dosage

المؤلفون: Yap TA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom., Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2012 Jul 15; Vol. 18 (14), pp. 3912-23. Date of Electronic Publication: 2012 Jul 10.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Neoplasms*/metabolism, Antineoplastic Agents/*administration & dosage , Phosphatidylinositol 3-Kinase/*metabolism , Protein Kinase Inhibitors/*administration & dosage, Apoptosis/drug effects ; Apoptosis/genetics ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Phosphoinositide-3 Kinase Inhibitors ; Phosphorylation/drug effects ; Pyrimidines/administration & dosage ; Pyrroles/administration & dosage ; Signal Transduction/drug effects ; Xenograft Model Antitumor Assays

المؤلفون: Witham J; Section of Medicine, The Institute of Cancer Research, Sutton, United Kingdom., Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2007 Dec 01; Vol. 13 (23), pp. 7191-8.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Biphenyl Compounds/*pharmacology , Carboplatin/*pharmacology , Nitrophenols/*pharmacology , Ovarian Neoplasms/*drug therapy , Paclitaxel/*pharmacology , Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors , Sulfonamides/*pharmacology , bcl-X Protein/*antagonists & inhibitors, Animals ; Apoptosis/drug effects ; Biphenyl Compounds/administration & dosage ; Carboplatin/administration & dosage ; Cell Line, Tumor ; Drug Administration Schedule ; Drug Synergism ; Female ; Humans ; Mice ; Nitrophenols/administration & dosage ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Piperazines/administration & dosage ; Piperazines/pharmacology ; RNA Interference ; RNA, Small Interfering/genetics ; Sulfonamides/administration & dosage ; Xenograft Model Antitumor Assays ; bcl-X Protein/genetics

المؤلفون: Gowan SM; Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK., Hardcastle A, Hallsworth AE, Valenti MR, Hunter LJ, de Haven Brandon AK, Garrett MD, Raynaud F, Workman P, Aherne W, Eccles SA

المصدر: Assay and drug development technologies [Assay Drug Dev Technol] 2007 Jun; Vol. 5 (3), pp. 391-401.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101151468 Publication Model: Print Cited Medium: Print ISSN: 1540-658X (Print) Linking ISSN: 1540658X NLM ISO Abbreviation: Assay Drug Dev Technol Subsets: MEDLINE

مواضيع طبية MeSH: Phosphoinositide-3 Kinase Inhibitors*, Chromones/*therapeutic use , Glycogen Synthase Kinase 3/*metabolism , Morpholines/*therapeutic use , Neoplasms, Experimental/*chemistry , Phosphoproteins/*analysis , Proto-Oncogene Proteins c-akt/*metabolism, Animals ; Cell Line, Tumor ; Female ; Glycogen Synthase Kinase 3 beta ; Humans ; Mice ; Neoplasm Transplantation ; Neoplasms, Experimental/drug therapy ; Reproducibility of Results ; Specimen Handling ; Transplantation, Heterologous